Navigation Links
Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
Date:11/24/2009

The molecular cause of inflammatory bowel disease is largely unknown, but research will be presented at the upcoming 2009 Advances in Inflammatory Bowel Diseases, the Crohn’s & Colitis Foundation’s Clinical & Research Conference, December 3-6 in Hollywood, Florida, that may identify a causative mutation for Crohn’s disease.

New York, NY (Vocus) November 24, 2009 -- The molecular cause of inflammatory bowel disease is largely unknown, but research will be presented at the upcoming 2009 Advances in Inflammatory Bowel Diseases, the Crohn’s & Colitis Foundation’s Clinical & Research Conference, December 3-6 in Hollywood, Florida, that may identify a causative mutation for Crohn’s disease. Evidence suggests that pathogenic mechanisms of Crohn’s disease may change with time, and the research abstract to be presented at the conference describes recessive mutations in the IL-10 receptor alpha and beta that may be causative for Crohn’s disease. The abstract was submitted by Dr. Bodo Grimbacher of the Department of Immunology and Molecular Pathology, Royal Free Hospital and University College London, and has recently been published in the New England Journal of Medicine (www.nejm.org, 11/4/09).

“This is very important and extremely exciting information, “says conference co-chair Richard P. MacDermott, MD of Albany Medical College. “Although just a first step in identifying the process that causes Crohn’s disease, eventually this may mean that successful treatment of patients may be possible using high local concentrations of interleukin-10.”

A record number of scientific abstracts have been submitted to the 2009 Advances in Inflammatory Bowel Diseases, outlining a broad scope of research projects. In addition to the IL-10 study, oral presentations will focus on improved patient outcomes, the use of new and emerging therapies, as well as better understanding the basis of the processes that cause Crohn’s disease and ulcerative colitis. Co-chair Stephen Hanauer, MD of the University of Chicago Medical Center emphasizes the need for a broad discussion of disease research and management options. “There are a number of unmet needs and challenges in the treatment of inflammatory bowel disease, such as the need for better inductive and maintenance agents that will improve both the patient's symptoms and quality of life. Ultimately, agents that will prevent and cure Crohn's disease and ulcerative colitis are still needed.”

Physicians, researchers, nurses and other health care professionals are invited to register for the conference, which will take place December 3-6,2009 in Hollywood, Florida, at www.advancesinibd.com. Conference attendees will gain insight from expert faculty on cutting-edge research breakthroughs and advancements in IBD patient care. More than 1,000 healthcare professionals are expected to attend the conference - the largest and most important annual event in the United States dedicated to the state-of-the-art in basic and clinical research as well as clinical management of patients with IBD. Inflammatory bowel diseases are inflammatory conditions of the large intestine and small intestine affecting over 1.4 million in the US alone.

About Crohn's Disease and Ulcerative Colitis
Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.

About the Crohn's & Colitis Foundation of America
The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with approximately 80 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact the Foundation at 800-932-2423 or visit www.ccfa.org.

About Imedex:
Imedex is dedicated to improving patient care through the education of medical professionals. We develop high quality scientific activities that translate the latest research into clinically relevant information. Our established relationships with leading investigators and researchers and some of the world’s most prestigious societies make our educational offerings the most effective in the industry. At Imedex, we believe that education is the best medicine®. www.imedex.com.

CONTACT:
Heather Drew
Imedex, LLC
Tel: +1 770 751 7332
h(dot)drew(at)imedex(dot)com

Ariella Levine
Crohn’s & Colitis Foundation
Tel. +1 646 943 7430
alevine(at)ccfa(dot)org

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3257764.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The book, ... for IT services, what questions to ask your IT consultant before signing a contract ... to your computer network. , “With companies relying heavily on e-mail and technology, it’s ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology: